Last NSCLC therapy prior to the first dose of osimertinib.
收藏数据链接：
官方服务：
资源简介：
Last NSCLC therapy prior to the first dose of osimertinib.
应用场景：
创建时间：
2024-05-16
相关数据集
Integrated bioinformatics and network pharmacology to explore the therapeutic target and molecular mechanisms of Taxus chinensis against NSCLC
Network pharmacology analysis data, including analysis process and results.
科学数据银行2022-06-21 更新40
Dataset from A Phase III Study to Assess the Efficacy of ZD6474 (ZACTIMA™) Plus Best Supportive Care Versus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer After Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI)
This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung can
NIAID Data Ecosystem40
Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
aberrations, including MET exon 14 skipping mutation and amplification, are present in ~5% of non-small cell lung cancer (NSCLC) cases, and these levels are comparable to the frequency of AL
Taylor & Francis Group2021-05-07 更新40
Studies included in the meta-analysis.
Abbreviations: MLND, mediastinal lymph node dissection; MLNS, mediastinal lymph node sampling; NSCLC, non-small cell lung cancer; ND, not derived.Studies included in the meta-analysis.
Figshare2015-12-02 更新40
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-small Cell Lung Cancer.. Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-small Cell Lung Cancer.
This SuperSeries is composed of the SubSeries listed below. Overall design: Refer to individual Series
NIAID Data Ecosystem40
